Competition in Russian market for anti-HIV drugs
The level of competition in the Russian market of anti-HIV drugs is tightening, due to the plans of global drugmakers to launch their products and expand their existing portfolios, The Pharma Letter’s local correspondent reports.
One of such companies is India’s Lok-Beta Pharmaceuticals, which has recently filed a lawsuit with the Russian Intellectual Rights Court (CIP) demanding that the patent rights of the Russian firm Pharmsynthez for lopinavir + ritonavir be annuled. The drug is used to treat and prevent HIV infection, while local analysts expect the level of competition in this market segment will only continue to grow in the coming years.
Pharmsynthez produces lopinavir + ritonavir under the brand name Kalidavir – which is a generic version of the drug Kaletra from the American company AbbVie (NYSE: ABBV). The generic appeared on the market back in 2018, bypassing the AbbVie patent, which is valid until 2024. Then Pharmasyntez registered water-insoluble polymers in its formula, while the US manufacturer had them water-soluble.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze